ADAR1 Capital Management’s RAPT Therapeutics RAPT Stock Holding History

ADAR1 Capital Management’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-509,679	Closed	-$17.3M	–	336
2025 Q4	$17.3M	Buy	509,679 +1,908	+0.4%	+$59.3K	1.27%	15
2025 Q3	$13.1M	Sell	507,771 -275,446	-35%	-$3.6M	1.23%	16
2025 Q2	$6.27M	Buy	783,217 +36,871	+5%	+$281K	0.96%	27
2025 Q1	$7.28M	Buy	746,346 +599,557	+408%	+$5.9M	1.35%	18
2024 Q4	$1.86M	Buy	146,789 +145,851	+15,549%	+$1.85M	0.37%	51
2024 Q3	$15.1K	Hold	938	–	–	﹤0.01%	248
2024 Q2	$22.9K	Buy	+938	New	+$43.3K	﹤0.01%	215

ADAR1 Capital Management's RAPT Position: Q1 2026 in Review

ADAR1 Capital Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 509,679 shares — an estimated $17.3M sold.

ADAR1 Capital Management first reported a position in RAPT in Q2 2024 and held it in 7 quarters. The position peaked at $17.3M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

ADAR1 Capital Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
ADAR1 Capital Management sold 509,679 RAPT Therapeutics shares in Q1 2026, an estimated $17.3M.
ADAR1 Capital Management first reported a position in RAPT Therapeutics in Q2 2024 and held it in 7 quarters.
ADAR1 Capital Management's RAPT Therapeutics position peaked at $17.3M in Q4 2025.
0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.